Discovering New Acetylcholinesterase Inhibitors by Mining the Buzhongyiqi Decoction Recipe Data
暂无分享,去创建一个
Hao Wang | Yu Wang | Xinxin Zhou | Jun Xu | Zhihong Liu | Lu Cui | Hongzhuan Chen | Hao Wang | Zhihong Liu | Jun Xu | Hongzhuan Chen | Xinxin Zhou | Yu Wang | Lu Cui
[1] Holger Gohlke,et al. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.
[2] Sorel Muresan,et al. Developing a drug-like natural product library. , 2008, Journal of natural products.
[3] Lorenzo Maggi,et al. Treatment of Myasthenia Gravis , 2011, Clinical drug investigation.
[4] E. Giacobini,et al. Cholinesterase inhibitors: new roles and therapeutic alternatives. , 2004, Pharmacological research.
[5] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[6] Xin Yan,et al. LBVS: an online platform for ligand-based virtual screening using publicly accessible databases , 2014, Molecular Diversity.
[7] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[8] Trevor Hughes,et al. The early history of myasthenia gravis , 2005, Neuromuscular Disorders.
[9] Xue Xu,et al. A System-Level Investigation into the Mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for Cardiovascular Disease Treatment , 2012, PloS one.
[10] K. Courtney,et al. A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.
[11] Bruno Eymard,et al. Diagnostic and clinical classification of autoimmune myasthenia gravis. , 2014, Journal of autoimmunity.
[12] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .
[13] G. Klebe. Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.
[14] Nils Erik Gilhus,et al. Myasthenia Gravis: A Review of Available Treatment Approaches , 2011, Autoimmune diseases.
[15] Monica Milani,et al. Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.
[16] D. Normile. The New Face of Traditional Chinese Medicine , 2003, Science.
[17] Yang Sun,et al. Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen. , 2013, Journal of medicinal chemistry.
[18] Ping Liu,et al. Clinical treatment of myasthenia gravis with deficiency of spleen and kidney based on combination of disease with syndrome theory. , 2013, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.
[19] Wei Zhou,et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines , 2014, Journal of Cheminformatics.
[20] Dennis Normile,et al. Asian medicine. The new face of traditional Chinese medicine. , 2003, Science.
[21] Xin Yan,et al. GSA: a GPU-accelerated structure similarity algorithm and its application in progressive virtual screening , 2012, Molecular Diversity.
[22] Holger Gohlke,et al. The Amber biomolecular simulation programs , 2005, J. Comput. Chem..
[23] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[24] M. Kurukumbi,et al. Myasthenia Gravis: A Review , 2012, Autoimmune diseases.
[25] Wolfgang Sippl,et al. Molecular Modeling of Potential Anticancer Agents from African Medicinal Plants , 2014, J. Chem. Inf. Model..
[26] V. Hornak,et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.
[27] John C. Keesey,et al. Clinical evaluation and management of myasthenia gravis , 2004, Muscle & nerve.
[28] A Szobor,et al. On the treatment of myasthenia gravis. , 1969, Acta medica Academiae Scientiarum Hungaricae.
[29] H. Kaminski,et al. Treatment of Myasthenia Gravis , 2011, Current neurology and neuroscience reports.
[30] Minghao Zheng,et al. Enhancing Molecular Shape Comparison by Weighted Gaussian Functions , 2013, J. Chem. Inf. Model..
[31] Ruibo Wu,et al. Molecular Dynamics-Based Virtual Screening: Accelerating the Drug Discovery Process by High-Performance Computing , 2013, J. Chem. Inf. Model..
[32] Jun Xu. A new approach to finding natural chemical structure classes. , 2002, Journal of medicinal chemistry.
[33] Xin Yan,et al. gWEGA: GPU‐accelerated WEGA for molecular superposition and shape comparison , 2014, J. Comput. Chem..
[34] P. Williams,et al. Natural products as a source of Alzheimer's drug leads. , 2011, Natural product reports.
[35] S. Berrih-Aknin,et al. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. , 2014, Journal of autoimmunity.
[36] P. Kollman,et al. Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.
[37] Xin Yan,et al. Big data in drug design , 2015 .
[38] Peng Jiang,et al. Molecular networks for the study of TCM Pharmacology , 2010, Briefings Bioinform..
[39] F. Schumm,et al. Symptomatische Therapie bei Myasthenia gravis und anderen neuromuskulären Übertragungsstörungen , 2011 .
[40] Mankil Jung,et al. Acetylcholinesterase inhibition by flavonoids from Agrimonia pilosa. , 2007, Molecules.
[41] Abdul Malik,et al. Cholinesterase Inhibitory Constituents from Onosma hispida. , 2003 .
[42] J. Pearce,et al. Mary Broadfoot Walker (1888–1974): A Historic Discovery in Myasthenia gravis , 2004, European Neurology.
[43] M. Rudolph,et al. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. , 2012, Journal of medicinal chemistry.